Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $61.0052W HIGH $187.69
Volume
1.75 M
Value Traded
256.98 M
Short % Float
8.55%
+5.34%Week
+16.3%1 Month
+14.92%3 Month
+100.66%6 Month
-3.01%5 Year
+328.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
25.12 B
EPS (TTM)
-3.38
P/E Ratio
-
Ent. Value
25.57 B
Total Shares
134.21 M
Float Shares
128.82 M
Insiders
4.01%
Institutions
101.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GH Catalyst Timeline
Dated clinical, regulatory and corporate events for Guardant Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Guardant Health, Inc.
224Total events
4Upcoming
67Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationPresentation
Poster P2.184: Impact of Common Resistance Mechanisms on Real-World Overall Survival for Patients Receiving Osimertinib
NSCLCsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
FDA approves Guardant360 CDx as companion diagnostic for ETCAMAH in advanced breast cancer
HR-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutationssource ↗
▼IP Litigation RulingIP / Competition
Final judgment entered in patent infringement suit against Guardant Health
▲Product LaunchShieldApprovedPost-Market
UnitedHealth Group covers Shield blood test for colorectal cancer screening
colorectal cancer screeningsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
FDA approval of Guardant360 CDx as companion diagnostic for Boehringer Ingelheim's HERNEXEOS
companion diagnostic for HERNEXEOSsource ↗
▲Other Regulator MilestoneShieldApprovedEx-US Regulatory
American Cancer Society recommends Shield blood test in updated CRC screening guidelines
colorectal cancer screeningsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
FDA approval of Guardant360 CDx as companion diagnostic for VEPPANU (vepdegestrant)
ER+/HER2- advanced breast cancer with ESR1 mutationssource ↗
▲Partnership / LicenseCorporate
Multi-year strategic collaboration with Nuvalent to develop companion diagnostics
oncologysource ↗
▲FDA Approvalardant360ApprovedFDA Decision
FDA approval of Guardant360 CDx as companion diagnostic for HERNEXEOS
HER2 (ERBB2)-mutant advanced non-small cell lung cancersource ↗
▲FDA ApprovalShieldApprovedFDA Decision
FDA approval for higher-throughput, lower-COGS Shield workflow
colorectal cancer screeningsource ↗
▲Reimbursement / PricingShieldApprovedPost-Market
Shield coverage obtained from UnitedHealth Group
colorectal cancer screeningsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
First Guardant360 CDx companion diagnostic approval in colorectal cancer
colorectal cancersource ↗
▲Product LaunchPost-Market
Expanded tissue-free Guardant Reveal to include late-stage therapy response monitoring
late-stage therapy response monitoringsource ↗
●FDA Filing AcceptedRegulatory Filing
Submitted Guardant Reveal chemotherapy monitoring data package to MolDx for Medicare reimbursement
chemotherapy monitoringsource ↗
▲Partnership / LicenseCorporate
Established strategic collaboration with Merck to develop companion diagnostics and commercialize new cancer therapies
▲Product LaunchShieldApprovedPost-Market
Shield CRC received coverage through TRICARE for active-duty service members and families
colorectal cancer screeningsource ↗
◆Oral PresentationPresentation
Guardant Health to participate in upcoming investor conferences
◆Quarterly UpdateCorporate
Planned Q4 and full year 2025 audited financial results earnings call
▲FDA Approvalardant360ApprovedFDA Decision
FDA approval of Guardant360 CDx as companion diagnostic for BRAFTOVI combination in BRAF V600E-mutant mCRC
BRAF V600E-mutant metastatic colorectal cancersource ↗
▲Partnership / LicenseCorporate
Multi-year strategic collaboration with Merck to develop companion diagnostics and commercialize new cancer therapies using Guardant Infinity Smart platform
oncologysource ↗
▲Partnership / LicenseCorporate
Announced collaboration with Nuvalent to develop companion diagnostics
▲FDA Approvalardant360ApprovedFDA Decision
FDA approved Guardant360 CDx as companion diagnostic for VEPPANU
ER+/HER2- ESR1 mutated advanced breast cancersource ↗
▲Partnership / LicenseShieldApprovedCorporate
Launched nationwide multi-year collaboration with Quest to expand Shield access
colorectal cancer screeningsource ↗
▲Product LaunchPost-Market
Launched Shield Multi-Cancer Detection in Asia through Manulife partnership
multi-cancer detectionsource ↗
▼Equity OfferingCorporate
Pricing of upsized underwritten public offering of 3,333,333 shares at $90.00 per share
▼Equity OfferingCorporate
Completed follow-on public offering of common stock and issued convertible notes
▲Product LaunchShieldApprovedPost-Market
Expanded Shield to include multi-cancer detection (MCD) nationwide
multi-cancer detectionsource ↗
▲Partnership / LicenseShieldApprovedCorporate
Established strategic collaborations with Quest Diagnostics and PathGroup for Shield access
colorectal cancer screeningsource ↗
▲Partnership / LicenseCorporate
Established partnership with American Cancer Society
cancer screeningsource ↗
●NDA Submissionardant360ApprovedRegulatory Filing
Submitted Guardant360 Liquid PMA application to FDA
cancersource ↗
●FDA Filing AcceptedRevealFiledRegulatory Filing
Submitted Reveal immuno-oncology monitoring data package to MolDx for Medicare reimbursement
immuno-oncology monitoringsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
Received new Guardant360 companion diagnostic approval for non-small cell lung cancer
non-small cell lung cancersource ↗
▲Timing GuidancePresentation
Remainder of business excluding Screening expected to reach free cash flow breakeven in Q4 2025
●FDA Filing AcceptedRevealFiledRegulatory Filing
Submitted Reveal breast cancer package to MolDx for Medicare reimbursement
breast cancersource ↗
●PublicationRevealFiledPresentation
Published RADIOHEAD study for Reveal in Cancer Research Communications
pan-cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How GH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Guardant Health, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every GH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Shield blood test | colorectal cancer | 2023-05-09 | sensitivity: 83%; specificity: 90%; stage I III sensitivity: 73%; localized case sensitivity: 70%Read More | Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield blood test Shield blood test achieved overall 83% sensitivity and 90% specificity and demonstRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Eltoukhy HelmyDirector, Officer (Co-Chief Executive Officer) | Option | 23,997 1,966,320 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 7.4 % (48 %) | 509.10 M | 3.39 M | 1.65% ( 55.07 K) |
GH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GH ranks across every disease it competes in
Competitive Position is a premium feature
See how GH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGH News
GH▲ +4.6%today
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
Guardant Health has announced the publication of the COSMOS-MEL01 study results in Cancer Research Communications. This study is significant as it is the first prospective, multicenter evaluation of the Guardant Reveal™ blood test, which is designed for detecting molecular residual disease and monitoring recurrence in melanoma patients. The findings support the test's utility in clinical settings.
Read more →GHGuardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health announced that its Shield blood test for colorectal cancer screening will be covered by EviCore by Evernorth, effective January 1, 2027. This decision follows the American Cancer Society guidelines and signifies a notable expansion in the test's commercial adoption. EviCore, a major specialty benefits manager, operates in over 23 states.
Read more →GHGuardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
Guardant Health, a precision oncology company, will present 20 abstracts at the 2026 World Conference on Lung Cancer. These presentations will focus on advancements in methylation-based tumor classification and liquid biopsy technology for lung cancer subtypes. The conference is organized by the International Association for the Study of Lung Cancer.
Read more →GHBusiness Insider Names Guardant Health One of America's Most Innovative Businesses
Guardant Health, Inc. has been recognized by Business Insider as one of America's Most Innovative Businesses for 2027. The company received a five-star rating, the highest available, and is among only 12 biotechnology research companies to achieve this distinction. This recognition highlights Guardant's innovative performance over the past five years.
Read more →GHGuardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
Guardant Health has received FDA approval for its Guardant360® CDx as a companion diagnostic for AstraZeneca's ETCAMAH™ in advanced breast cancer. This approval allows for the identification of HR-positive, HER2-negative patients with ESR1 mutations who may benefit from camizestrant treatment. This marks a significant step in precision oncology for breast cancer management.
Read more →GHGuardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
Guardant Health, Inc. announced that its Shield blood test for colorectal cancer screening will be covered by Carelon Healthcare Services starting November 15. Carelon is a significant specialty benefits manager in the U.S., enhancing the test's accessibility across more than 14 states. This coverage marks an important step for colorectal cancer detection.
Read more →GHGuardant Health to Appeal Federal District Court Judgment
Guardant Health, Inc. has announced plans to appeal a final judgment from the U.S. District Court for the District of Delaware regarding intellectual property claims by TwinStrand Biosciences and the University of Washington. The execution of the judgment and any potential royalty collections are currently stayed pending the outcome of the appeal. Guardant Health expresses strong disagreement with the court's decision.
Read more →GHTwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest
TwinStrand Biosciences announced a favorable final judgment from the U.S. District Court in a patent infringement case against Guardant Health. The court awarded TwinStrand and the University of Washington over $245.2 million in damages, royalties, and interest. This ruling upholds a previous jury verdict that found Guardant Health willfully infringed on TwinStrand's patents.
Read more →GHGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health has announced the approval of restricted stock units (RSUs) for 149 new non-executive employees. The RSUs, totaling 46,044 shares, are part of the company's 2023 Employment Inducement Incentive Award Plan. This initiative reflects Guardant's strategy to attract and retain talent as it continues to grow in the precision oncology sector.
Read more →GH▲ +6.3%on this news
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health, Inc. reported its financial results for the second quarter of 2026, showing a significant increase in total revenue of 44% year-over-year. The oncology segment contributed $219.1 million, marking a 38% rise. Additionally, the company performed approximately 104,000 oncology tests, a 63% increase from the prior year.
Read more →GH▲ +5.7%on this newsshared move
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, a leader in precision oncology, has announced its participation in two upcoming investor conferences. The company will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12 and the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 15. These events provide a platform for the company to engage with investors and discuss its innovations.
Read more →GHActor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
Guardant Health has launched a tribute video featuring Patrick Dempsey to honor over 55,000 Americans who will die from colorectal cancer this year. The video emphasizes the critical need for timely colorectal cancer screenings, as many victims are not up to date with their screenings. This initiative aims to raise awareness and encourage preventive measures.
Read more →GHGuardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
Guardant Health, a precision oncology company, will report its second quarter 2026 financial results on July 30, 2026. The announcement includes a conference call scheduled for 1:30 p.m. PT, which will be webcasted for investor access. This event highlights the company's commitment to transparency and investor relations.
Read more →GHUnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening
UnitedHealth Group has announced that it will now cover Guardant Health's Shield Blood Test for colorectal cancer screening. This test provides a non-invasive method for detecting colorectal cancer, which could lead to earlier diagnosis and treatment. The coverage expansion is expected to enhance access to this innovative screening option for patients.
Read more →GHGuardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
Guardant Health has received FDA approval for its Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS®. This approval marks a significant advancement in personalized medicine, allowing for better-targeted therapies. The collaboration aims to improve patient outcomes by providing more precise treatment options.
Read more →GHGuardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health, alongside collaborators, will present 38 abstracts at the 2026 ASCO Annual Meeting. These abstracts will showcase the breadth and expanded clinical utility of Guardant's liquid biopsy tests, enhanced by their InfinityAI technology. This presentation aims to highlight advancements in cancer diagnostics and treatment monitoring.
Read more →GH▲ +6.4%on this newsshared move
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
The American Cancer Society has updated its colorectal cancer screening guidelines to include Guardant Health's Shield blood test. This endorsement is expected to enhance early detection efforts for colorectal cancer. The inclusion of the Shield test reflects a growing recognition of non-invasive screening methods in cancer care.
Read more →GH▲ +17.1%on this news
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
The FDA has approved the new Guardant360 Liquid CDx, marking it as the largest liquid biopsy panel available. This approval expands its footprint by 100 times, significantly enhancing diagnostic capabilities in oncology. The approval reflects the FDA's confidence in the technology's effectiveness in providing critical insights for patient care.
Read more →GHDocument Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening Raises 2026 revenu
Guardant Health reported a remarkable 48% increase in revenue for Q1 2026, reaching $301.7 million, driven by strong performances in oncology and screening sectors. The company adjusted its revenue guidance for the full year 2026 to between $1.30 and $1.32 billion, reflecting anticipated growth in oncology and screening contributions. Despite these positive developments, Guardant faced increasing operating expenses and a net loss of $112.1 million, raising concerns about profitability. The company has also expanded its capabilities and partnerships in precision oncology, enhancing its competitive position in the market.
Read more →About Guardant Health, Inc.
Headquarters3100 HANOVER STREET, PALO ALTO, CA, 94304
BIOPHARMAWATCH ELITE PLUS
Trade the next GH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime